OSCR enters the final stretch before its August 6 Q2 print with shorts entrenched near multi-month highs, a CEO who sold roughly $54 million of stock in a single week, and a stock trading above where most analysts think it belongs.
The short position has stabilised this week rather than extended further. Short interest held near 18.9 million shares — 8.3% of the free float — essentially flat from the sharp single-session jump on July 10 that was the focus of our previous report. That stability matters: bears rebuilt aggressively, and they haven't retreated. The week-on-week increase is still 10.8%, and the one-month build is 13%. This is a position that was constructed with intent and is being held. The lending market does nothing to threaten it — availability is effectively unlimited, with over 248 million shares still available to borrow against fewer than 19 million short. Cost to borrow has ticked back up to 0.43% after briefly dipping, but remains negligible. Options traders are also drifting slightly more defensive: the put/call ratio edged to 0.45, modestly above its 20-day average of 0.42 and at its highest reading in roughly three weeks, though still well clear of the 52-week high of 1.17. Nothing in the options market signals panic — just a gradual lean toward caution as the earnings date approaches.
The CEO selling is the most striking data point of the past two weeks. Mark Bertolini offloaded more than 1.8 million shares between June 25 and June 30 at prices ranging from $28.35 to $30.08 — total proceeds of approximately $54 million. Founder Mario Schlosser sold a further 47,500 shares on July 1. Net insider activity over the past 90 days shows over $103 million in net sales. That is a significant amount of supply delivered into the rally, and it tells a clear story about where at least two major insiders assessed fair value. Notably, the institutional ownership table offers a partial counterweight: BlackRock added 1.26 million shares as of June 30, and Dimensional added 760,000. American Century also added nearly 1 million shares in the same period. The picture at the institutional level is mixed rather than uniformly bearish.
The Street's positioning is quietly awkward. Barclays upgraded to Overweight with a $35 target in mid-June — the most recent material analyst move, and one that sits just above the current price of $31.07. But the consensus mean target is $24.20, well below where the stock trades. That gap reflects a Street that largely hasn't caught up with the 10% monthly rally. Factor scores tell a more positive story on fundamentals: EPS surprise ranks in the 95th percentile, and 90-day EPS momentum is in the 99th percentile — the company has been consistently beating estimates by a wide margin. The bull case rests on that earnings power: 29% revenue growth in the most recent quarter, an improving medical loss ratio of 91.1%, and projected premium-per-member growth of 28.5% in 2026. The bear case is structural: potential expiration of enhanced ACA subsidies could strip out 20-30% of individual marketplace enrollment, threatening roughly 6.1 million members. That policy risk is exactly the kind of binary overhang that keeps short interest elevated even when near-term results look strong.
After the last two earnings prints, the stock moved sharply higher — roughly 16% on the day and 32% over the following five sessions for the May report, and 20% on the day with a 41% five-day move after the June 4 release. Bears positioned ahead of those prints were wrong, and wrong badly. The question heading into August 6 is whether the same dynamic plays out, or whether the enrollment risk from subsidy expiration finally begins to show up in guidance. Shorts holding 8.3% of the float into that print are making a specific bet that this time the numbers disappoint, or that management guidance pulls the stock back toward consensus target levels.
What to watch: whether short interest holds at current levels or sees further accumulation in the three weeks between now and the August 6 earnings release, and whether the gap between the current price and the $24.20 consensus target begins to close through analyst upgrades or through price.
See the live data behind this article on ORTEX.
Open OSCR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
